FDA Oncology Announcements

EZH inhibitor × Clear all

4 Announcements

FDA granted accelerated approval to tazemetostat for follicular lymphoma

Drug: TAZVERIK (tazemetostat) · EZH inhibitor
Condition: Lymphoid

FDA granted accelerated approval to tazemetostat for follicular lymphoma

Drug: TAZVERIK (tazemetostat) · EZH inhibitor
Condition: Lymphoid

FDA approves tazemetostat for advanced epithelioid sarcoma

Drug: TAZVERIK (tazemetostat) · EZH inhibitor
Condition: Sarcoma

FDA approves tazemetostat for advanced epithelioid sarcoma

Drug: TAZVERIK (tazemetostat) · EZH inhibitor
Condition: Sarcoma